NASDAQ:VRAY ViewRay (VRAY) Stock Price, News & Analysis → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free VRAY Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.03▼$0.6552-Week Range N/AVolume108.50 million shsAverage Volume7.51 million shsMarket Capitalization$4.59 millionP/E RatioN/ADividend YieldN/APrice Target$1.33 Stock AnalysisStock Analysis Get ViewRay alerts: Email Address ViewRay MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside∞ Upside$1.00 Price TargetShort InterestN/ADividend StrengthN/ASustainability-1.57Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.61 out of 5 stars 3.0 Analyst's Opinion Consensus RatingViewRay has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageViewRay has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for VRAY. Previous Next 0.0 Dividend Strength Dividend YieldViewRay does not currently pay a dividend.Dividend GrowthViewRay does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreViewRay has received a 67.89% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "MRI machines", "Radiation therapy machines", and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for ViewRay is -1.57. Previous Next N/A News and Social Media Coverage Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ViewRay insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.50% of the stock of ViewRay is held by insiders.Percentage Held by Institutions92.97% of the stock of ViewRay is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of ViewRay is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ViewRay is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The TradingPubAt first glance, this chart looks like nonsense…We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”But if you want the stock with “Hotspot Dates” hitting NEXT WEEK… About ViewRay Stock (NASDAQ:VRAY)ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally. It provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers through a network of direct sales force and distributors. ViewRay, Inc. was founded in 2004 and is headquartered in Denver, Colorado.Read More Ad Crypto Swap ProfitsHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here VRAY Stock News HeadlinesMarch 16, 2024 | finance.yahoo.comVRAY Jan 2025 2.000 callMarch 16, 2024 | finance.yahoo.comVRAY Jan 2025 0.500 putApril 24, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…March 16, 2024 | finance.yahoo.comVRAY Jan 2025 0.500 callMarch 16, 2024 | finance.yahoo.comVRAY Jan 2025 3.000 putNovember 4, 2023 | morningstar.comViewRay Inc VRAYQNovember 1, 2023 | benzinga.comNUBURU Appoints Brian Knaley as new CEOOctober 19, 2023 | tmcnet.comOpen Letter to ViewRay Customers, Service, Software Engineers and Suppliers-Let's Preserve ViewRay TechnologyApril 24, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.October 17, 2023 | benzinga.comLetter to ViewRay Lenders/Investment Bankers and Customers From Krishnan Suthanthiran, President/Founder of TeamBest Global CompaniesAugust 20, 2023 | ca.finance.yahoo.comViewRay Inc (6L9.BE)July 21, 2023 | seekingalpha.comViewRay stock to be delisted from Nasdaq and moved to OTC ExchangeJuly 21, 2023 | finance.yahoo.comViewRay® Announces Commencement of Nasdaq Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC MarketsJuly 18, 2023 | benzinga.comWhy ViewRay Stock Hit A New 52-Week Low TodayJuly 18, 2023 | finanznachrichten.deViewRay, Inc.: ViewRay Files Voluntary Chapter 11 PetitionsJuly 17, 2023 | msn.comWhy ViewRay (VRAY) Stock Hit A New 52-Week Low TodayJuly 17, 2023 | investorplace.comWhy Is ViewRay (VRAY) Stock Down 69% Today?July 17, 2023 | finance.yahoo.comViewRay® Files Voluntary Chapter 11 PetitionsJuly 7, 2023 | msn.comViewRay: Near-Term Bankruptcy Filing Might Be In The Cards - SellMay 26, 2023 | fool.comViewRay (NASDAQ: VRAY)May 25, 2023 | markets.businessinsider.comViewray (VRAY) Receives a Hold from Stifel NicolausMay 16, 2023 | finance.yahoo.comDo You Believe in the Growth Prospects of ViewRay (VRAY)?May 13, 2023 | msn.comMorgan Stanley Maintains ViewRay (VRAY) Equal-Weight RecommendationMay 12, 2023 | finance.yahoo.comNeed To Know: The Consensus Just Cut Its ViewRay, Inc. (NASDAQ:VRAY) Estimates For 2023May 12, 2023 | finance.yahoo.comViewRay's MRIdian® to be Featured at Leading European Radiation Oncology MeetingMay 11, 2023 | finanznachrichten.deViewRay, Inc.: ViewRay Announces First Quarter 2023 ResultsMay 11, 2023 | markets.businessinsider.comB.Riley Financial downgrades Viewray (VRAY) to a HoldSee More Headlines Receive VRAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ViewRay and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2023Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryN/A Current SymbolNASDAQ:VRAY CUSIPN/A CIK1597313 Webwww.viewray.com Phone(440) 703-3210Fax800-417-3459Employees295Year Founded2004Price Target and Rating Average Stock Price Target$1.00 High Stock Price Target$1.00 Low Stock Price Target$1.00 Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-107,330,000.00 Net Margins-104.30% Pretax Margin-104.30% Return on Equity-120.48% Return on Assets-42.39% Debt Debt-to-Equity RatioN/A Current Ratio1.16 Quick Ratio0.91 Sales & Book Value Annual Sales$105.86 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.45 per share Price / BookN/AMiscellaneous Outstanding Shares183,402,000Free Float178,817,000Market Cap$4.59 million OptionableOptionable Beta0.81 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Scott William Drake (Age 55)Pres, CEO & Director Comp: $1.8MMr. Robert S. McCormack J.D. (Age 56)Chief Legal Officer Comp: $692.36kDr. James F. Dempsey Ph.D. (Age 52)Founder & Chief Scientific Officer Mr. William P. Burke (Age 54)Exec. VP & CFO Drew HillSr. VP of Operations & Devel.Matt HarrisonDirector of Investor RelationsKaren HackstaffVP of MarketingMr. Robert Michael Fuchs (Age 56)Chief HR Officer Dr. Martin Fuss M.D.Ph.D., Chief Medical OfficerMr. Paul Ziegler Jr. (Age 49)J.D., Exec. VP & Chief Commercial Officer More ExecutivesKey CompetitorsHelius Medical TechnologiesNASDAQ:HSDTENDRA Life SciencesNASDAQ:NDRANuwellisNASDAQ:NUWETivic Health SystemsNASDAQ:TIVCBioSig TechnologiesNASDAQ:BSGMView All CompetitorsInsidersSanket ShahSold 30,364 sharesTotal: $2,125.48 ($0.07/share)Karen PrangeSold 37,600 sharesTotal: $1,880.00 ($0.05/share)Farhad Fred EbrahimiSold 8,203,610 sharesTotal: $492,216.60 ($0.06/share)Paul Ziegler JrSold 169,785 sharesTotal: $11,884.95 ($0.07/share)B Kristine JohnsonSold 79,622 sharesTotal: $5,573.54 ($0.07/share) VRAY Stock Analysis - Frequently Asked Questions Should I buy or sell ViewRay stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ViewRay in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" VRAY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VRAY, but not buy additional shares or sell existing shares. View VRAY analyst ratings or view top-rated stocks. What is ViewRay's stock price target for 2024? 1 brokers have issued twelve-month price targets for ViewRay's shares. Their VRAY share price targets range from $1.00 to $1.00. On average, they anticipate the company's share price to reach $1.00 in the next twelve months. View analysts price targets for VRAY or view top-rated stocks among Wall Street analysts. How were ViewRay's earnings last quarter? ViewRay, Inc. (NASDAQ:VRAY) released its earnings results on Monday, February, 27th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.01. The business earned $34.70 million during the quarter, compared to the consensus estimate of $34.65 million. ViewRay had a negative trailing twelve-month return on equity of 120.48% and a negative net margin of 104.30%. The business's quarterly revenue was up 70.1% compared to the same quarter last year. During the same quarter last year, the company posted ($0.16) EPS. What is Scott Drake's approval rating as ViewRay's CEO? 5 employees have rated ViewRay Chief Executive Officer Scott Drake on Glassdoor.com. Scott Drake has an approval rating of 59% among the company's employees. This puts Scott Drake in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of ViewRay own? Based on aggregate information from My MarketBeat watchlists, some companies that other ViewRay investors own include Alibaba Group (BABA), Amarin (AMRN), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), AbbVie (ABBV), Accuray (ARAY) and Selecta Biosciences (SELB). When did ViewRay IPO? ViewRay (VRAY) raised $52 million in an IPO on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and BTIG and Brean Capital were co-managers. Does ViewRay have any subsidiaries? The following companies are subsidiares of ViewRay: Vesuvius Acquisition Corp., ViewRay GmbH, and ViewRay Technologies Inc..Read More This page (NASDAQ:VRAY) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingNew Trump BombshellThe Freeport SocietyThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ViewRay, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
